Skip to Content
Merck
CN

S2155000

Sulfasalazine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-Hydroxy-5-{{4-[(2-pyridinylamino)sulfonyl]phenyl}azo}benzoic acid, 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic acid, Salicylazosulfapyridine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H14N4O5S
CAS Number:
599-79-1
Molecular Weight:
398.39
PubChem Substance ID:
329824508
UNSPSC Code:
41116107
Beilstein/REAXYS Number:
356241
MDL number:
MFCD00057363

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3

InChI

1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

InChI key

NCEXYHBECQHGNR-QZQOTICOSA-N

API family

sulfasalazine

mp

260-265 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... ALOX5(240), PTGS1(5742), PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfasalazine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 2 - Carc. 2 - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 2

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shekoufeh Nikfar et al.
Digestive diseases and sciences, 54(6), 1157-1170 (2008-09-05)
Historically, sulfasalazine (SSZ) and 5-aminosalicylates (5-ASAs) have been a mainstay of mild-to-moderate ulcerative colitis (UC) remission induction and maintenance therapy. Considering the pivotal role of intestinal microbial flora in pathophysiology of UC and antimicrobial activity of sulfapyridine, we hypothesized that
J R O'Dell
Rheumatic diseases clinics of North America, 24(3), 465-477 (1998-08-26)
Combinations of DMARDs are currently used to treat rheumatoid arthritis by almost all rheumatologists. This article reviews the published data on the triple combination of methotrexate, sulfasalazine, and hydroxychloroquine, discusses caveats for clinical use, compares efficacy of different combinations, and
Junmin Chen et al.
The Journal of rheumatology, 33(4), 722-731 (2006-04-04)
To evaluate the efficacy and toxicity of sulfasalazine (SSZ) for the treatment of ankylosing spondylitis (AS). We searched randomized and quasi-randomized trials in any language comparing SSZ with placebo in treatment of AS. Two reviewers independently selected the studies and
James Dale et al.
Nature clinical practice. Rheumatology, 3(8), 450-458 (2007-08-01)
Early aggressive treatment of rheumatoid arthritis is associated with improved disease control, slower radiological progression and improved functional outcomes. Tumor necrosis factor blocking therapy is effective but there remain concerns about long-term risks. Combining disease-modifying antirheumatic drugs (DMARDs) is a
Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications.
Ronni Wolf et al.
Clinics in dermatology, 20(5), 531-546 (2002-11-19)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service